SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
March 11, 2024
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
October 30, 2024 RegulatorySynAct Pharma publishes Q3 2024 interim results
-
October 18, 2024 Non RegulatorySynAct Pharma to attend BIO-Europe in Stockholm November 4-6
-
September 23, 2024 Non RegulatorySynAct initiates the Phase 2b ADVANCE study with resomelagon (AP1189) in the US
The interim report for Q3 2024 was published on October 30, 2024, at 07.30 CEST.
A MESSAGE FROM OUR CEO
”There are more than 400,000 newly diagnosed patients each year in the Western World of which a large fraction would benefit from treatment with resomelagon as a new effective and safe treatment option.